Physician profile
Behnam Jafarpour
NPI 1033359336
$45,285.95
in general payments reported to CMS, 2019-2025
65 companies · $14K in 2025
The $14K reported for 2025 was more than what 98% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $829 · 2021: $567 · 2022: $1,926 · 2023: $2,949 · 2024: $23K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $9,874 · Travel and Lodging: $1,423 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,875.00 |
| Food and Beverage | $9,873.59 |
| Travel and Lodging | $1,422.78 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33,269.16 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,276.70 | 2019-2025 | |
| Lundbeck LLC | $955.77 | 2021-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $809.25 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $755.27 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Biogen, INC. | $702.36 | 2019-2025 | Tysabri, Leqembi, Vumerity |
| Pfizer INC. | $591.82 | 2023-2025 | |
| Abbott Laboratories | $498.31 | 2022-2025 | Proclaim, Eterna |
| Lilly USA, LLC | $493.95 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Eisai INC. | $422.71 | 2022-2025 | |
| Genentech USA, INC. | $392.14 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Ucb, INC. | $391.85 | 2019-2025 | Briviact, Rystiggo |
| Emd Serono, INC. | $335.43 | 2019-2025 | Mavenclad |
| Sumitomo Pharma America, INC. | $303.32 | 2023-2024 | Aptiom |
| Genzyme Corporation | $279.57 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behnam Jafarpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.